Of course the market debacle will influence M&A, dealmaking. The pendulum is swinging back to buyers
Do you think certain M&A targets look more interesting to you given the significant pullback in biotech valuations? Or do you still think some of these good assets are overvalued? And do you think companies and boards of mid-cap biotechs have capitulated to valuation resets, or will that take more time?
Louise Chen at Cantor Fitzgerald didn’t waste any time in getting to one of the big biopharma questions of 2022: Are we about to see a surge of M&A and deals now? And how does the bear market in biotech stocks influence that?
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.